Key Highlights

  • Moderna (NASDAQ:MRNA) fell 7.23% premarket on October 26, 2026 even though the INTerpath-001 melanoma data showed a recurrence-free survival hazard ratio of 0.58, a 42% lower relative risk, with Merck in published market data.
  • The Moderna and Merck results were dated October 22, 2026, so the Monday decline is not explained by new trial information and the cause was not established in the information available.
  • Eledon Pharmaceuticals (NASDAQ:ELDN) faces a short seller report dated October 23 that cites going-concern language and a USD 75 million at-the-market facility ahead of a 620-patient Phase 3, which are allegations only.
  • Genmab (NASDAQ:GMAB) jumped 12% in European trading on October 26 on a positive late-stage trial update, while the trial name, the results and the move in the US-listed receipt were not available.

Moderna (NASDAQ:MRNA): Cancer Vaccine Data and a Fall

Moderna (NASDAQ:MRNA) and Merck reported Phase 3 results from the INTerpath-001 trial of an individualized neoantigen therapy, a personalized cancer vaccine, in melanoma. The trial showed a recurrence-free survival hazard ratio of 0.58 and a distant metastasis-free survival hazard ratio of 0.62. The company release was dated October 22, 2026, and Merck shares moved 1.1% lower that day, yet the 7.23% fall for Moderna is dated October 26 in published market data. Because the data were already public by then, the Monday decline is not explained by new trial information, and the specific cause was not available for this article. Moderna's partner Merck is a much larger company, so its shares reacted less to the same news. A hazard ratio compares the rate of events, here cancer recurrence or death, in the treated group with the rate in the comparison group over time. A ratio of 0.58 means the treated group had about 42% fewer events at any given moment, a relative reduction and not an absolute one. A ratio of 0.62 for distant metastasis-free survival means a 38% lower relative risk of cancer spreading, simple arithmetic. The results were presented as a late-breaker at the European Society for Medical Oncology congress and published in the New England Journal of Medicine. Investors sometimes sell after good data when the result was widely expected, a pattern known as selling the news. Regulatory approval of a personalized vaccine requires review of manufacturing, safety and durability of benefit. The data are for melanoma patients after surgery, and results may not apply to other tumor types. Moderna also faces pricing pressure for its respiratory vaccines and heavy research spending.

Eledon Pharmaceuticals (NASDAQ:ELDN): Short Seller Report

A short seller published a report on October 23, 2026, and its claims were still being discussed on October 26. According to the report, Eledon Pharmaceuticals (NASDAQ:ELDN) lacks enough cash to fund a 620-patient Phase 3 trial and will need to sell equity within 60 to 90 days. The report cites going-concern language and an at-the-market facility of USD 75 million. These are allegations. The company's response and its latest cash balance were not available for this article, and the claims were not independently checked. A reader should check the cash figure, the quarterly burn rate and the facility terms in the company's SEC filings. Cash runway is the number of months a company can operate before it needs funding, and it is the central test of the allegation. Going-concern language is a statement in a company's financial statements that management or auditors see substantial doubt about its ability to continue operating for at least twelve months without new funding. An at-the-market facility lets a company sell shares gradually into the open market through a broker, at prevailing prices, up to a stated amount. Each sale adds shares and dilutes existing holders, so a stock can fall even when a trial goes well. A USD 75 million facility gives flexibility but also means that new shares can reach the market without a fixed announcement date. A Phase 3 trial of 620 patients is expensive, because it requires many sites, long follow-up and data management. If the claims are right, dilution could follow, and a trial that runs short of money could be delayed. If they are wrong, the report may prove to be a short-term shock for the shares.

Genmab (NASDAQ:GMAB): Late-Stage Trial Update

Genmab, a biotechnology company based in Denmark, saw its shares rise 12% in European trading on Monday, October 26, 2026 after a positive update from a late-stage trial, according to published market data. A late-stage trial, usually Phase 3, tests a treatment in a large group of patients and is the last major step before regulatory submission. The information available for this article did not name the trial or give the results, such as survival or response rates, so no clinical figure is stated here. Genmab (NASDAQ:GMAB) trades in the United States as an American depositary receipt, and the US move was not available. The company is known for antibody-based cancer medicines and partnerships with larger drug makers. An American depositary receipt is a certificate that represents shares of a foreign company and trades on a US exchange in dollars. If the news came after the European close or before the US open, the US shares could react differently. Biotech investors usually look at the primary endpoint, safety, the comparison group and the timing of regulatory filings. The headline number is often only part of the story, so analysts read the full data once they are published. Positive headline results can be followed by declines if full data show safety concerns or a smaller benefit than expected. Late-stage success also does not guarantee approval or commercial sales. Genmab faces competition in cancer treatments and depends on partnerships and royalties. Investors can watch the full data release, presentation at a medical meeting, regulatory submission plans and the US trading session on October 27, 2026. The Federal Reserve decision on October 28 may also affect biotech sentiment.

Where Things Stand

The answer is that biotech shares are reacting to three different kinds of news: strong data that did not stop a fall at Moderna (NASDAQ:MRNA), a short seller allegation at Eledon Pharmaceuticals and a positive update at Genmab. Headlines do not tell the full story in any of the three. Regulatory plans, company filings and full trial data are the next tests. Next filings from Moderna (NASDAQ:MRNA) will add detail. Fresh disclosure from Eledon Pharmaceuticals (NASDAQ:ELDN) is the next test. Official notices from Genmab (NASDAQ:GMAB) remain the best guide. Further disclosure from Genmab (NASDAQ:GMAB) would clarify the picture.